Moreover, a study investigating tumor microenvironment, demonstrated that the use of low doses of the anti-VEGF receptor 2 (VEGFR2) antibody was able to polarize the immune inhibitory M2-like phenotype towards the immune stimulatory M1-like phenotype and to recruit CD4+ and CD8+ T-cells. This evidence concerns the gene CD8A and neoplasm.